MONTREAL, CANADA--(Marketwire - November 29, 2007) - ART Advanced Research Technologies Inc. (“ART”)(TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be exhibiting at the American Society for Cell Biology (ASCB) 47th Annual Meeting, Dec. 1-5, 2007, Washington, DC. ART will showcase its preclinical product offering, including the Optix® MX2 optical imaging device and the Fenestra® line of contrast agents for micro-CT imaging at its booth (#853) located in the Exhibit Hall of the Washington Convention Center. ART’s Optix MX2 platform enhances molecular imaging research for the life scientist. By applying ART’s proprietary time domain technology to biology a scientist can gain incremental sensitivity, specificity, and depth data from fluorescent labelled compounds. This technique can apply to specific receptors, antibodies, epitopes and drugs for in vivo preclinical research.